Suppr超能文献

促甲状腺激素受体在甲状腺乳头状癌亚型中的表达及临床意义

Expression and Clinical Significance of Thyroid-stimulating hormone receptor in the Subtypes of Papillary thyroid carcinomas.

作者信息

Shen Wei, Zhang Shanshan, Li Qinghuai

机构信息

Wei Shen, Department of Thyroid and Breast Surgery, The Second Hospital of Hebei Medical University, 215 Peace West Road, Shijiazhuang 050000, Hebei, P.R. China.

Shanshan Zhang, Department of Thyroid and Breast Surgery, The Second Hospital of Hebei Medical University, 215 Peace West Road, Shijiazhuang 050000, Hebei, P.R. China.

出版信息

Pak J Med Sci. 2023 Jan-Feb;39(1):198-202. doi: 10.12669/pjms.39.1.6096.

Abstract

OBJECTIVE

To investigate the expression of TSH receptors (TSHR) in various subtypes of Papillary thyroid carcinomas (PTC) by immunohistochemistry.

METHODS

Retrospective analyses were carried out to the clinical data of 108 PTC patients randomly admitted into the Department of Thyroidthyroid surgery thyroid surgery and Breast Surgery, The Second Hospital of Hebei Medical University from March 2020 to December 2020. The archived paraffin blocks of the 108 cases as well as 18 contiguous normal thyroid tissues (control group) were taken from the Department of Pathology of The Second Hospital of Hebei Medical University. The pathological types of all PTC tissues were detected and the expression of TSHR was determined.

RESULTS

TSHR expression was 86.11% positive in PTC tissues; with 85.00% positive in classical group; with 75.86% positive in micro group; with 84.61% positive in follicular group; with 83.33% positive in oncocytic group; with 50.00% positive in invasive group. TSHR expression was 100% in normal thyroid tissues. So TSHR expression in normal thyroid tissues is significantly higher than that in PTC; TSHR expression in microcarcinoma is stronger than in the other subtypes; there is no significant difference among the other subtypes.

CONCLUSIONS

TSH suppression works better on microcarcinoma than on the other subtypes. And the effects on non-invasive subtypes are better than on invasive subtypes.

摘要

目的

采用免疫组织化学方法研究促甲状腺激素受体(TSHR)在甲状腺乳头状癌(PTC)各亚型中的表达情况。

方法

回顾性分析2020年3月至2020年12月随机入住河北医科大学第二医院甲状腺乳腺外科的108例PTC患者的临床资料。这108例病例的存档石蜡块以及18例相邻正常甲状腺组织(对照组)取自河北医科大学第二医院病理科。检测所有PTC组织的病理类型并测定TSHR的表达。

结果

PTC组织中TSHR表达阳性率为86.11%;经典型组阳性率为85.00%;微小癌组阳性率为75.86%;滤泡型组阳性率为84.61%;嗜酸细胞型组阳性率为83.33%;浸润型组阳性率为50.00%。正常甲状腺组织中TSHR表达为100%。所以正常甲状腺组织中TSHR表达显著高于PTC;微小癌中TSHR表达强于其他亚型;其他亚型之间无显著差异。

结论

促甲状腺激素抑制对微小癌的效果优于其他亚型。对非浸润性亚型的效果优于浸润性亚型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b965/9842975/3d740ee28486/PJMS-39-198-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验